Biosight Announces Initiation of Investigator Sponsored Phase 2 Clinical Trial of Aspacytarabine for Relapsed/Refractory AML and MDS with the Groupe Francophone des Myélodysplasies

NEXT STORY
The global market for liquid handling systems is predicted to grow at a CAGR of 7.43% over the forecast period 2021-2031
PREV STORY
Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

author_avatar
NASDAQ Market News

FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

FIT Biotech Oy Company release October 17, 2018 at 06:15 PM EET Conversion of ...

author_avatar
NASDAQ Market News

Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

author_avatar
NASDAQ Market News